Literature DB >> 35319999

Apoptosis: Directly Targeted at Last.

Anthony Letai1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35319999      PMCID： PMC9113207          DOI： 10.1200/JCO.22.00304

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  20 in total

1.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Authors:  John F Seymour; Shuo Ma; Danielle M Brander; Michael Y Choi; Jacqueline Barrientos; Matthew S Davids; Mary Ann Anderson; Anne W Beaven; Steven T Rosen; Constantine S Tam; Betty Prine; Suresh K Agarwal; Wijith Munasinghe; Ming Zhu; L Leanne Lash; Monali Desai; Elisa Cerri; Maria Verdugo; Su Young Kim; Rod A Humerickhouse; Gary B Gordon; Thomas J Kipps; Andrew W Roberts
Journal:  Lancet Oncol       Date:  2017-01-13       Impact factor: 41.316

2.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.

Authors:  Tomomi Kuwana; Lisa Bouchier-Hayes; Jerry E Chipuk; Christine Bonzon; Barbara A Sullivan; Douglas R Green; Donald D Newmeyer
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

3.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

6.  Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.

Authors:  C Du; M Fang; Y Li; L Li; X Wang
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

7.  Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.

Authors:  P Li; D Nijhawan; I Budihardjo; S M Srinivasula; M Ahmad; E S Alnemri; X Wang
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

Review 8.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.

Authors:  S J Korsmeyer; M C Wei; M Saito; S Weiler; K J Oh; P H Schlesinger
Journal:  Cell Death Differ       Date:  2000-12       Impact factor: 15.828

9.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

10.  Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.

Authors:  Claire N Harrison; Jacqueline S Garcia; Tim C P Somervaille; James M Foran; Srdan Verstovsek; Catriona Jamieson; Ruben Mesa; Ellen K Ritchie; Srinivas K Tantravahi; Pankit Vachhani; Casey L O'Connell; Rami S Komrokji; Jason Harb; Jessica E Hutti; Leanne Holes; Abdullah A Masud; Silpa Nuthalapati; Jalaja Potluri; Naveen Pemmaraju
Journal:  J Clin Oncol       Date:  2022-02-18       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.